FluoGuide Förvaltning

Förvaltning kriterier kontrolleras 2/4

FluoGuide VD är Morten Albrechtsen, utsedd i Jan 2018, har en anställningstid på 7.17 år. äger direkt 10.93% av företagets aktier, värda SEK 66.22M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 5.2 år respektive 3.8 år.

Viktig information

Morten Albrechtsen

Verkställande direktör

n/a

Total ersättning

VD-lön i procent	n/a
Anställning som VD	7.2yrs
Ägande av VD	10.9%
Ledningens genomsnittliga anställningstid	5.2yrs
Styrelsens genomsnittliga mandatperiod	3.8yrs

Senaste uppdateringar av ledningen

Recent updates

VD OCH KONCERNCHEF

Morten Albrechtsen (60 yo)

7.2yrs

Anställning

Mr. Morten Albrechtsen, M.D., BBA, has been the CEO at Fluoguide A/s since 2018. He is the Co-founder and serves as the Chief Executive Officer at radiotherapy specialists Nanovi ApS. Mr. Albrechtsen Found...

Ledningsgrupp

Namn	Position	Anställning	Kompensation	Ägarskap
Morten Albrechtsen	Chief Executive Officer	7.2yrs	inga uppgifter	10.93% SEK 66.2m
Ole Larsen	Chief Financial Officer	2.1yrs	inga uppgifter	inga uppgifter
Andreas Kjaer	CSO, Head of Scientific Advisory Board & Director	no data	inga uppgifter	15.61% SEK 94.6m
Grethe Rasmussen	Chief Development Officer	6.2yrs	inga uppgifter	inga uppgifter
Jens Ellrich	Chief Medical Officer	less than a year	inga uppgifter	inga uppgifter
Dorthe Mejer	Vice President of Clinical Development	5.2yrs	inga uppgifter	inga uppgifter

5.2yrs

Genomsnittlig anställningstid

60.5yo

Genomsnittlig ålder

Erfaren ledning: FLUO s ledningsgrupp är erfaren och erfaren ( 5.2 års genomsnittlig anställning).

Styrelseledamöter

Namn	Position	Anställning	Kompensation	Ägarskap
Andreas Kjaer	CSO, Head of Scientific Advisory Board & Director	7.2yrs	inga uppgifter	15.61% SEK 94.6m
Mats Thoren	Vice Chairman of the Board	3.8yrs	inga uppgifter	inga uppgifter
Donna Haire	Director	1yr	inga uppgifter	inga uppgifter
Peter Eriksen	Independent Chairman	6.2yrs	inga uppgifter	inga uppgifter
Michael Engsig	Independent Director	2yrs	inga uppgifter	inga uppgifter

3.8yrs

Genomsnittlig anställningstid

55yo

Genomsnittlig ålder

Erfaren styrelse: FLUO s styrelse anses vara erfaren ( 3.8 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2025/03/05 12:34
Aktiekurs vid dagens slut	2025/03/05 00:00
Intäkter	2024/12/31
Årlig intjäning	2024/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

FluoGuide A/S bevakas av 1 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Christian Binder	Redeye

FluoGuide Förvaltning

Förvaltning kriterier kontrolleras 2/4

Viktig information

Senaste uppdateringar av ledningen

Fluoguide A/S Announces Roger Gunnarsson Resigns as Board Member

Fluoguide A/S Announces Executive Changes

Less than half of directors are independent

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer

Recent updates

Forecast breakeven date pushed back to 2027

Here's Why We're Watching FluoGuide's (STO:FLUO) Cash Burn Situation

FluoGuide A/S Receives Approval for Phase II Trial in Head and Neck Cancer

New minor risk - Share price stability

FluoGuide A/S to Report Q3, 2025 Results on Nov 27, 2025

FluoGuide A/S Announces Publication of Positive Phase II Clinical Data for FG001 in Patients with Head and Neck Cancer

Fluoguide A/S Announces Roger Gunnarsson Resigns as Board Member

FluoGuide A/S Submits Clinical Trial Application for Phase II Trial in Head and Neck Cancer

New major risk - Financial position

Fluoguide A/S Announces Executive Changes

FluoGuide A/S to Report Fiscal Year 2024 Final Results on Feb 27, 2025

Less than half of directors are independent

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

New major risk - Revenue and earnings growth

No longer forecast to breakeven

FluoGuide A/S to Report Q2, 2024 Results on Aug 29, 2024

New minor risk - Share price stability

FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001

New minor risk - Shareholder dilution

FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer

FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference

Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague

New minor risk - Profitability

Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer

FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer

Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer

FluoGuide A/S to Report Q3, 2023 Results on Nov 29, 2023

FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

FluoGuide A/S Releases Positive Interim Result of FG001 in Head and Neck Cancer

FluoGuide A/S, Annual General Meeting, Mar 21, 2023

FluoGuide A/S to Report Fiscal Year 2022 Results on Feb 28, 2023

FluoGuide A/S Enrolls First Patient in the Phase IIa Trial in Head and Neck Cancer

FluoGuide A/S Reaches Milestone with FG001 for Phase III Clinical Supply

FluoGuide A/S Releases Positive Interim Result of FG001-CT002

FluoGuide A/S Enrolls the First Patient in the Phase IIb Trial in Aggressive Brain Cancer

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide A/S Presents the Outstanding Clinical Data from the Completed Phase I/IIa Trial with FG001 in Patients with Aggressive Brain Cancer Undergoing Surgery, At the World Molecular Imaging Congress

FluoGuide A/S Ordinary Shares to Be Deleted from OTC Equity

FluoGuide A/S Receives Approval from the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Head and Neck Cancer

FluoGuide Announces CFO Changes

FluoGuide Receives Permission to Start Phase IIb Trial in Aggressive Brain Cancer

Fluoguide A/S Update on Fg001's Clinical Development

FluoGuide Submits a Clinical Trial Application (CTA) to the Danish Medicines Agency to Initiate Phase II Trial with FG001 in Head and Neck Cancer

FluoGuide Publish the Presentation of FG001 Results from the First Clinical Trial in Aggressive Brain Cancer

We're Hopeful That FluoGuide (STO:FLUO) Will Use Its Cash Wisely

FluoGuide A/S Announces Positive Top Line Result from Ongoing Clinical Phase I/II Trial

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide Submits Clinical Trial Application to the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Lung Cancer

Fluoguide Proceeds to Seventh Dose Level with Fg001 in the Ongoing Clinical Phase I/II Trial Following Continued Improvement of Tumor Illumination with Increasing Doses

FluoGuide Announces Regulatory Approval from Swedish Authorities to Commence Phase II Clinical Trial with FG001 in Guiding Surgery of High Grade Glioma in Sweden

FluoGuide A/S Announces Publication of Promising Preclinical Data on FG001 Effect in Treatment of Cancer

FluoGuide A/S Announces Promising Preclinical Data with Fg002 Technology in Guiding Surgical Removal of Cancer

FluoGuide has Received Green Light to Proceed to the Next Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients Undergoing Surgical Treatment of High Grade Glioma

FluoGuide Receives Approval to Commence with FG001 in Evening Dosing in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

FluoGuide A/S Acquires Rights to Photothermal Therapy Using FG001

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

Dose Escalation Committee Approves FluoGuide A/S's Initiation of the Fourth Dose Level in the Ongoing Clinical Phase I/II Trial Evaluating Safety and Efficacy of Fg001 in Patients with High Grade Glioma Undergoing Neurosurgery

Chairman Arne Ferstad has left the company

Fluoguide A/S Announces Management Changes At the Annual General Meeting Held on February 9, 2021

Fluoguide A/S Announces Publication of Two Patent Applications Covering the Company's uPAR Technology Platform for Improving Surgery

FluoGuide A/S to Report Nine Months, 2021 Results on Nov 24, 2021

New 90-day high: kr.132

FluoGuide A/S Gets Green Light to Proceed to Second Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

New 90-day low: kr.46.20

FluoGuide A/S Announces First Patient Enrolled in the Phase I/II Clinical Trial Testing FG001 in Patients with High Grade Glioma

FluoGuide Appoints Henrik Moltke as Chief Financial Officer, Effective December 2020

New 90-day high - kr.40.00